Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

Abstract

HepatologyVolume 37, Issue 5 p. 1220-1221 CorrespondenceFree Access Noninvasive prediction of fibrosis in patients with chronic hepatitis C Dominique Thabut M.D., Dominique Thabut M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorMarion Simon M.D., Marion Simon M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorRobert P. Myers M.D., Robert P. Myers M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorDjamila Messous M.D., Djamila Messous M.D. Department of Biochemistry, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorVincent Thibault Ph.D., Vincent Thibault Ph.D. Department of Virology, Groupe Hospitalier Pitié-Salpêtrière, Paris, FranceSearch for more papers by this authorFrançoise Imbert-Bismut Ph.D., Françoise Imbert-Bismut Ph.D. Department of Biochemistry, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorThierry Poynard M.D., Ph.D., Thierry Poynard M.D., Ph.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this author Dominique Thabut M.D., Dominique Thabut M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorMarion Simon M.D., Marion Simon M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorRobert P. Myers M.D., Robert P. Myers M.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorDjamila Messous M.D., Djamila Messous M.D. Department of Biochemistry, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorVincent Thibault Ph.D., Vincent Thibault Ph.D. Department of Virology, Groupe Hospitalier Pitié-Salpêtrière, Paris, FranceSearch for more papers by this authorFrançoise Imbert-Bismut Ph.D., Françoise Imbert-Bismut Ph.D. Department of Biochemistry, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this authorThierry Poynard M.D., Ph.D., Thierry Poynard M.D., Ph.D. Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié-Salpê;trière, Paris, FranceSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2003.50109Citations: 74AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986– 992. 2 Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069– 1075. 3 Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 2002; 9: 128– 133. 4 Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated interferon alfa-2b and ribavirin combination [Abstract]. Hepatology 2002; 36(Part 2): 351A. 5 Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003 (in press). 6 Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: prospective validation in 534 patients [Abstract]. Hepatology 2002; 36(Part 2): 351A. 7 Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. Life is possible without biopsy in patients with chronic hepatitis C: validation of biochemical markers of liver fibrosis and activity in 1570 patients and blood donors [Abstract]. Hepatology 2002; 36(Part 2): 351A. 8 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839– 843. 9 Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428– 434. 10 Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. The effect of treatment with pegylated interferon alfa-2b and ribavirin on hepatic steatosis in patients infected with hepatitis C virus genotype 3 [Abstract]. Hepatology 2002; 36(Part 2): 284A. Citing Literature Volume37, Issue5May 2003Pages 1220-1221 ReferencesRelatedInformation